Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus 2024 per tanggal 30 November 2024 (994 artikel)
Publikasi Scopus 2024 per tanggal 30 November 2024 (994 artikel)
Kroeze, Stefanie (57202014804); Kootstra, Neeltje A. (6603966335); Van Nuenen, Ad C. (6506182226); Rossouw, Theresa M. (23095586200); Kityo, Cissy M. (6602918610); Siwale, Margaret (36138961600); Akanmu, Sulaimon (57294759700); Mandaliya, Kishor (35427966200); De Jager, Marleen (57202001797); Ondoa, Pascale (6507124442); Wit, Ferdinand W. (57226231723); Reiss, Peter (7005073010); Rinke De Wit, Tobias F. (6603948874); Hamers, Raph L. (23034345900)
Specific plasma microRNAs are associated with CD4+T-cell recovery during suppressive antiretroviral therapy for HIV-1
2024
AIDS
38
6
791
801
10
0
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190079084&doi=10.1097%2fQAD.0000000000003853&partnerID=40&md5=0beaaa8b87ede9ecf9a6f0a9b03d5f88
Amsterdam Institute for Global Health and Development, Netherlands; Amsterdam UMC Location, University of Amsterdam, Department of Global Health, Netherlands; Amsterdam UMC Location, University of Amsterdam, Laboratory for Experimental Immunology, Meibergdreef 9, Amsterdam, Netherlands; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands; Department of Immunology, University of Pretoria, Pretoria, South Africa; Joint Clinical Research Centre, Kampala, Uganda; Lusaka Trust Hospital, Lusaka, Zambia; Department of Haematology and Blood Transfusion, College of Medicine, University of Lagos, Lagos University Teaching Hospital, Lagos, Nigeria; Coast Province General Hospital, Mombasa, Kenya; Muelmed Hospital, Pretoria, South Africa; African Society for Laboratory Medicine, Addis Ababa, Ethiopia; Stichting HIV Monitoring; Amsterdam UMC Location, University of Amsterdam, Internal Medicine, Division of Infectious Diseases, Meibergdreef 9, Amsterdam, Netherlands; Oxford University, Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom
Objective:This study investigated the association of plasma microRNAs before and during antiretroviral therapy (ART) with poor CD4+T-cell recovery during the first year of ART.Design:MicroRNAs were retrospectively measured in stored plasma samples from people with HIV (PWH) in sub-Saharan Africa who were enrolled in a longitudinal multicountry cohort and who had plasma viral-load less than 50 copies/ml after 12 months of ART.Methods:First, the levels of 179 microRNAs were screened in a subset of participants from the lowest and highest tertiles of CD4+T-cell recovery (ΔCD4) (N = 12 each). Next, 11 discordant microRNAs, were validated in 113 participants (lowest tertile ΔCD4: n = 61, highest tertile ΔCD4: n = 52). For discordant microRNAs in the validation, a pathway analysis was conducted. Lastly, we compared microRNA levels of PWH to HIV-negative controls.Results:Poor CD4+T-cell recovery was associated with higher levels of hsa-miR-199a-3p and hsa-miR-200c-3p before ART, and of hsa-miR-17-5p and hsa-miR-501-3p during ART. Signaling by VEGF and MET, and RNA polymerase II transcription pathways were identified as possible targets of hsa-miR-199a-3p, hsa-200c-3p, and hsa-miR-17-5p. Compared with HIV-negative controls, we observed lower hsa-miR-326, hsa-miR-497-5p, and hsa-miR-501-3p levels before and during ART in all PWH, and higher hsa-miR-199a-3p and hsa-miR-200c-3p levels before ART in all PWH, and during ART in PWH with poor CD4+T-cell recovery only.Conclusion:These findings add to the understanding of pathways involved in persistent HIV-induced immune dysregulation during suppressive ART. © 2024 Lippincott Williams and Wilkins. All rights reserved.
HIV Infections; HIV-1; Humans; MicroRNAs; Retrospective Studies; T-Lymphocytes; app protein; cav2 protein; complementary DNA; cyclin dependent kinase inhibitor 1A; early growth response factor 2; excitatory amino acid transporter 2; hemochromatosis protein; hepatocyte nuclear factor 3beta; Hermes antigen; hsa microRNA 17 5p; hsa microRNA 199a 3p; hsa microRNA 200c 3p; hsa microRNA 501 3p; igfbp3; klf9 protein; low density lipoprotein receptor; mefd2 protein; microRNA; mouse double minute 2 homolog; nonnucleoside reverse transcriptase inhibitor; paimp1 protein; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; protein bcl 2; ptpro protein; Rho family GTPase 3; RNA polymerase II; scatter factor receptor; transcription factor Sp1; transforming growth factor beta receptor 2; unclassified
Jura Foundation; Gilead Sciences Netherlands; Heineken Africa Foundation, HAF; Nederlandse Organisatie voor Wetenschappelijk Onderzoek, NWO, (91615036, W07.10.101, W07.10.106); Nederlandse Organisatie voor Wetenschappelijk Onderzoek, NWO; Ministerie van Buitenlandse Zaken, (12454); Ministerie van Buitenlandse Zaken
Funding text 1: The PanAfrican Studies to Evaluate Resistance (PASER) is an initiative of the Amsterdam Institute for Global Health and Development, with major support provided by the Ministry of Foreign Affairs of The Netherlands through a partnership with Stichting Aids Fonds (12454), and with additional support from De Grote Onderneming, The Embassy of the Kingdom of the Netherlands, Heineken A
Lippincott Williams and Wilkins
02699370
38300257
Article
Q1
1401
2523